Artificial nucleic acid molecules

US11697816B2 · kind B2 · utility

Assignee

• CureVac SE · DE

Inventors

• Stefanie GRUND · Stuttgart, DE
• Thomas SCHLAKE · Gundelfingen, DE

Key dates

• Filing date: Jun 28, 2016
• Grant date: Jul 11, 2023
• Expiry date: Jun 28, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2840/203
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to an artificial nucleic acid molecule comprising at least one open reading frame and at least one 3′-untranslated region element (3′-UTR element) comprising a nucleic acid sequence which is derived from the 3′-UTR of a FIG4 gene or from a variant of the 3′-UTR of a FIG4 gene. The invention further relates to the use of such an artificial nucleic acid molecule in gene therapy and/or genetic vaccination. Furthermore, the invention relates to the use of a 3′-UTR element comprising a nucleic acid sequence which is derived from the 3′-UTR of a FIG4 gene or from a variant of the 3′-UTR of a FIG4 gene for the stabilization and/or prolongation of protein expression from a nucleic acid sequence comprising such 3′-UTR element.